<DOC>
	<DOCNO>NCT01791153</DOCNO>
	<brief_summary>This multicenter , randomize , double-blind , placebo-controlled study evaluate efficacy safety RoActemra/Actemra ( tocilizumab ) patient giant cell arteritis . Patients randomize receive either RoActemra/Actemra 162 mg subcutaneously weekly every 2 week placebo 52 week , taper oral daily dose prednisone . After Week 52 , patient remission stop study treatment enter long-term follow-up , whereas patient disease activity flare receive open-label RoActemra/Actemra 162 mg subcutaneously weekly maximum period 104 week discretion investigator . Anticipated time study 39 month .</brief_summary>
	<brief_title>A Study RoActemra/Actemra ( Tocilizumab ) Patients With Giant Cell Arteritis</brief_title>
	<detailed_description />
	<mesh_term>Arteritis</mesh_term>
	<mesh_term>Giant Cell Arteritis</mesh_term>
	<mesh_term>Polymyalgia Rheumatica</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>Diagnosis giant cell arteritis classify accord follow criterion : Age &gt; /= 50 year History ESR &gt; /= 50 mm/hour least one following : Unequivocal cranial symptom giant cell arteritis Symptoms polymyalgia rheumatica least one follow Temporal artery biopsy reveal feature giant cell arteritis Evidence largevessel vasculitis New onset active disease ( diagnosis within 6 week baseline ) refractory active disease ( diagnosis &gt; 6 week baseline previous treatment &gt; /= 40 mg/day prednisone ( equivalent ) least 2 consecutive week time ) ; active disease define presence clinical sign symptom ESR &gt; /= 30 mm/hour CRP &gt; /= 1 mg/dl within 6 week baseline Recent incoming major surgery Organ transplantation recipient ( except cornea within 3 month prior baseline visit ) Major ischemic event , unrelated giant cell arteritis , within 12 week screen Prior treatment follow : Investigational agent within 12 week ( 5 halflives investigational drug , whichever long ) screen visit Celldepleting agent ( e.g . anti CD 20 ) Tocilizumab Tofacitinib Alkylating agent include CYC within 6 month baseline HCQ , CsA , AZA , MMF within 4 week baseline Tumor necrosis factor inhibitor within 28 week baseline Anakinra within 1 week baseline Corticosteroids condition GCA IV corticosteroid within 6 week baseline History severe allergic reaction monoclonal antibody Evidence serious uncontrolled concomitant disease ( e.g . cardiovascular , respiratory , renal , endocrine ) Current liver disease could interfere trial determined investigator History diverticulitis , inflammatory bowel disease , symptomatic GI tract condition might predispose bowel perforation Infections : Active current history recurrent bacterial , viral fungal , mycobacterial , infection Prior episode major infection Active TB require treatment within previous 3 year Untreated latent TB infection ( LTBI ) Primary secondary immunodeficiency Malignancy ( except basal squamous cell carcinoma skin carcinoma situ cervix uterus excise cure ) Inadequate hematologic , renal liver function Positive hepatitis B hepatitis C infection</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>